Secondary Antibodies 同型对照 WB内参抗体 蛋白电泳 WB转印膜组 WB底物 Labeling Kits WB Catalog # 31458 Invitrogen Donkey anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, HRP CNY 2,377.00 Unit Size : 500 µL 添加到购物车 Catalog # A11008 Invitrogen Goat anti-Rabbit...
provided Antigen binding molecules that include a first multi specific specificity Union joins PD - L1 and a Second specificity of Union that binds to an Antigen of tumor Cell, a cell specific antigen Co infected, or an inhibitor of t cells.In some forms of realization, the Antibodies are us...
1、Drew M. Pardoll. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. 2、Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 a...
2023年5月3日,南方科技大学第一附属医院邹畅教授团队和生物医学工程系微流控-生物材料实验室合作在Advanced Science期刊发表了题为:Microfluidics-enabled nano-vesicle delivers CD47/PD-L1 antibodies to enhance anti-tumor immunity and reduce immunotoxicity in lung adenocarcinoma 的研究论文。 该研究针对实体肿瘤酸性...
5.Kitagawa S, et al. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature revie...
参考文献：Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, Momtazi-Borojeni AA, Chen S. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer. 2021 Jan;9(1):e001698. doi: ...
[2].Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling[J]. Sci Rep. 2019 Aug 7;9(1):11472. [3].Jifeng Yu, Yongping Song, Wenzhi Tian. How to select IgG subclasses ...
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling[J]. Sci Rep. 2019 Aug 7;9(1):11472. 3、Jifeng Yu, Yongping Song, Wenzhi Tian. How to select IgG subclasses in developing anti-tumor therapeutic antibodies[J]. J Hematol Oncol. 2020 ...
even in models resistant to anti-PD-L1 antibodies. Exosomal PD-L1 from the tumor suppresses T cell activation in the draining lymph node. Systemically introduced exosomal PD-L1 rescues growth of tu- mors unable to secrete their own. Exposure to exo- somal PD-L1-deficient tumor cells suppresses...
5.Kitagawa S, et al. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Thorac Cancer. 2020 Jul;11(7):1927-1933. ...